KR880010764A - Hypercholesterolemic blood mixture - Google Patents

Hypercholesterolemic blood mixture Download PDF

Info

Publication number
KR880010764A
KR880010764A KR1019880003150A KR880003150A KR880010764A KR 880010764 A KR880010764 A KR 880010764A KR 1019880003150 A KR1019880003150 A KR 1019880003150A KR 880003150 A KR880003150 A KR 880003150A KR 880010764 A KR880010764 A KR 880010764A
Authority
KR
South Korea
Prior art keywords
sucrose
component
gum
composition
polyol polyester
Prior art date
Application number
KR1019880003150A
Other languages
Korean (ko)
Other versions
KR970004956B1 (en
Inventor
데이비드 브로드더스 챨스
Original Assignee
원본미기재
더 프록터 앤드 갬블 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 더 프록터 앤드 갬블 캄파니 filed Critical 원본미기재
Publication of KR880010764A publication Critical patent/KR880010764A/en
Application granted granted Critical
Publication of KR970004956B1 publication Critical patent/KR970004956B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Psyllium gum and polyol polyesters are administered orally to reduce blood cholesterol levels.

Description

과콜레스테롤혈증 치료용 혼합물Mixtures for the treatment of hypercholesterolemia

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (11)

(a) 차전자(psyllium seed) 검 또는 차전자 검의 원료; 및 (b) 비흡수성이고 비소화성인 폴리올 폴리에스테르로 이루어짐을 특징으로 하는, 혈중 콜레스테롤 농도를 감소시키는 물질의 조성물.(a) a psyllium seed gum or a raw material of a challone gum; And (b) a non-absorbent and non-digestible polyol polyester. 제 1 항에 있어서, 폴리올 폴리에스테르 성분 (b)가 슈크로즈 옥타올레에이트, 슈크로즈 옥타리놀레에이트, 슈크로즈 옥타팔미테이트 및 이들의 혼합물인 조성물.The composition of claim 1, wherein the polyol polyester component (b) is sucrose octaoleate, sucrose octalinoleate, sucrose octapalmitate and mixtures thereof. 제 2 항에 있어서, 성분(a);성분(b)의 중량비가 3:1 내지 1:3인 조성물.The composition of claim 2 wherein the weight ratio of component (a); component (b) is from 3: 1 to 1: 3. 제 1 항에 있어서, 지용성 비타민으로 강화된 조성물.The composition of claim 1, fortified with fat soluble vitamins. (a) 차전자 검 또는 차전자 검의 원료;및 (b) 비흡수성이고 비소화성인 폴리올 폴리에스테르;또는 (c)(a) 및 (b)의 혼합물의 안전 유효량을 환자에게 경구 투여함을 특징으로 하여, 혈중 콜레스테롤의 치료를 필요로 하는 환자의 혈중 콜레스테롤을 감소시키는 방법.characterized by administering orally to the patient a safe and effective amount of (a) a chager gum or a raw material of the chager gum; and (b) a non-absorbable and non-digestible polyol polyester; or (c) a mixture of A method of reducing blood cholesterol in a patient in need thereof. 제 5 항에 있어서, 성분(a) 1g 내지 30g 및 성분(b) 5g 내지 50g을 경구 섭취함을 특징으로 하는 방법.6. A method according to claim 5, characterized by oral ingestion of components (a) 1g to 30g and components (b) 5g to 50g. 제 6 항에 있어서, 장기 섭취함을 특징으로 하는 방법.7. The method of claim 6, characterized by long term ingestion. 제 7 항에 있어서, 매일 섭취함을 특징으로 하는 방법.8. A method according to claim 7, characterized by ingestion daily. 제 8 항에 있어서 하루에 2회 또는 3회에 걸쳐 일정한 간격으로 성분(a) 약 5g 내지 약 15g 및 성분(b) 약 15g 내지 약 50g을 매일 섭취함을 특징으로 하는 방법.9. The method of claim 8, wherein about 5g to about 15g of component (a) and about 15g to about 50g of component (b) are taken daily at regular intervals over two or three times a day. 제 5 항에 있어서, 폴리올 폴리에스테르가 슈크로즈 옥타올레에이트, 슈크로즈 옥타리놀레에이트, 슈크로즈 옥타팔미테이트 및 이들의 혼합물인 방법.6. The process of claim 5 wherein the polyol polyester is sucrose octaoleate, sucrose octalinoleate, sucrose octapalmitate and mixtures thereof. 제 5 항에 있어서, 치료 조성물에 지용성 비타민을 투여함을 포함하는 방법.6. The method of claim 5, comprising administering a fat soluble vitamin to the therapeutic composition. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019880003150A 1987-03-24 1988-03-24 Mixtures for treating hypercholesterolemia KR970004956B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US029,825 1987-03-24
US02982 1987-03-24
US07/029,825 US4849222A (en) 1987-03-24 1987-03-24 Mixtures for treating hypercholesterolemia

Publications (2)

Publication Number Publication Date
KR880010764A true KR880010764A (en) 1988-10-24
KR970004956B1 KR970004956B1 (en) 1997-04-10

Family

ID=21851092

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880003150A KR970004956B1 (en) 1987-03-24 1988-03-24 Mixtures for treating hypercholesterolemia

Country Status (14)

Country Link
US (1) US4849222A (en)
EP (1) EP0285201B1 (en)
JP (1) JP2581737B2 (en)
KR (1) KR970004956B1 (en)
AT (1) ATE79544T1 (en)
AU (1) AU620541B2 (en)
CA (1) CA1314230C (en)
DE (1) DE3873800T2 (en)
DK (1) DK167847B1 (en)
IE (1) IE61404B1 (en)
IL (1) IL85689A (en)
NZ (1) NZ223947A (en)
PH (1) PH26694A (en)
ZA (1) ZA882061B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100679290B1 (en) * 2005-06-30 2007-02-05 박정휘 A composition comprising an extract of ???­??­201 crude drug complex as an effective ingredient treating or preventing obesity

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579752A (en) * 1984-10-29 1986-04-01 At&T Bell Laboratories Enhanced corrosion resistance of metal surfaces
JPH0788318B2 (en) * 1986-08-06 1995-09-27 三菱レイヨン株式会社 Method for producing isobutylene
US4950140A (en) * 1987-09-14 1990-08-21 The Procter & Gamble Company Cookies containing psyllium
US5095008A (en) * 1987-09-14 1992-03-10 The Procter & Gamble Company Cookies containing psyllium
US5910317A (en) * 1988-01-11 1999-06-08 The Procter & Gamble Company Mixed compositions for treating hypercholesterolemia
US4978529A (en) * 1988-05-25 1990-12-18 Denick Jr John Easily dispersible psyllium compositions
US5149541A (en) * 1988-10-03 1992-09-22 The Procter & Gamble Company Psyllium-containing produces with a distribution of particle size
US5024996A (en) * 1989-12-05 1991-06-18 General Mills, Inc. R-T-E cereal with soluble fibers
US5026689A (en) * 1989-03-29 1991-06-25 General Mills, Inc. R-T-E cereal with psyllium
US5219570A (en) * 1989-08-10 1993-06-15 The Procter & Gamble Company Agglomerated psyllium husk containing edible acid
US6419911B1 (en) 1993-09-17 2002-07-16 Board Of Trustees Of Michigan State University Psyllium containing snack bars, processes for making these, and uses thereof
US5126150A (en) * 1990-10-01 1992-06-30 The Procter & Gamble Company Compositions containing psyllium
WO1992011019A1 (en) * 1990-12-20 1992-07-09 The Procter & Gamble Company Psyllium and cholestyramine compositions with improved palatability
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
AU3473193A (en) * 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
US5281584A (en) * 1992-02-28 1994-01-25 The Dow Chemical Company Effect of particle-size distribution of cellulose ethers on palatability of compositions
US5258181A (en) * 1992-03-02 1993-11-02 The Procter & Gamble Company Compositions containing psyllium
CA2131177C (en) * 1992-03-11 1997-08-05 Hing Cheung Tse Psyllium drink mix compositions containing granulated base
WO1993018756A1 (en) * 1992-03-20 1993-09-30 The Procter & Gamble Company Anion exchange resin compositions
US5234916A (en) * 1992-06-12 1993-08-10 The Proctor & Gamble Company Psyllium drink mix compositions
US5232698A (en) * 1992-06-12 1993-08-03 The Proctor & Gamble Company Psyllium drink mix compositions
US5338549A (en) * 1992-12-21 1994-08-16 The Procter & Gamble Company Powdered psyllium drink mix compositions containing antioxidant
US5422101A (en) * 1993-05-14 1995-06-06 The Procter & Gamble Company Cholesterol lowering drink mix compositions
US5384136A (en) * 1993-09-17 1995-01-24 Kellogg Company Psyllium-enriched dough products and method for making the same
US5384144A (en) * 1993-09-17 1995-01-24 Kellogg Company Psyllium enriched pasta products and method for making same
US5382443A (en) * 1993-09-17 1995-01-17 Kellogg Company Ready-to-eat cereals containing extruded pre-wetted psyllium
US5955123A (en) * 1996-10-21 1999-09-21 The Procter & Gamble Company Baked compositions comprising psyllium
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
NZ504269A (en) 1997-11-07 2002-02-01 Kellog Co Extruded intermediates containing a soluble fiber and an insoluble fiber and food products containing same
US6123978A (en) 1998-08-31 2000-09-26 Mcneil-Ppc, Inc. Stable salad dressings
US6248387B1 (en) 1998-11-05 2001-06-19 Kellogg Company Psyllium enriched baked snack foods
US7115297B2 (en) * 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
US7238380B2 (en) * 2000-02-22 2007-07-03 Suzanne Jaffe Stillman Water containing soluble fiber
US7892586B2 (en) 2001-02-22 2011-02-22 Suzanne Jaffe Stillman Water containing soluble fiber
US8178150B2 (en) 2000-02-22 2012-05-15 Suzanne Jaffe Stillman Water containing soluble fiber
JP2006506378A (en) 2002-10-24 2006-02-23 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン Combination therapy using 1-aminocyclohexane derivative and acetylcholinesterase inhibitor
KR20070104480A (en) 2003-05-27 2007-10-25 포레스트 래보러토리즈, 인코포레이티드 Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
JP2004352626A (en) * 2003-05-28 2004-12-16 Asahi Breweries Ltd Anticholesterol agent containing plant-derived component
AR046601A1 (en) * 2003-10-22 2005-12-14 Merz Pharma Gmbh & Co Kgaa USE OF DERIVATIVES 1- AMINOCICLOHEXANO TO MODIFY THE DEPOSITION OF AB FIBROSO PEPTIDES IN AMYLOIDOPATHY
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US20060079582A1 (en) * 2004-09-23 2006-04-13 Jeffrey Jonas Memantine for the treatment of childhood behavioral disorders
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
WO2007005898A2 (en) * 2005-07-05 2007-01-11 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99l2
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
EP2200598A1 (en) 2007-09-12 2010-06-30 Merz Pharma GmbH & Co. KGaA Interval therapy for the treatment of tinnitus
EP2085120A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance
DK2318832T3 (en) 2008-07-15 2014-01-20 Academia Sinica Glycan arrays on PTFE-like aluminum coated slides and related methods
TWI432188B (en) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases
CN102159201A (en) 2008-12-19 2011-08-17 莫茨药物股份两合公司 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
WO2011000563A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of weight disorders
US20120136005A1 (en) 2009-06-30 2012-05-31 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of anxiety
WO2011000562A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of certain movement disorders
WO2011000564A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of drug addiction
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
US20110294890A1 (en) 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
EP2665474A1 (en) 2011-01-20 2013-11-27 Merz Pharma GmbH & Co. KGaA Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss
WO2012171653A1 (en) 2011-06-15 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Sarizotan for use in the treatment of attention deficit hyperactivity disorder (adhd)
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
TW201412325A (en) 2012-06-20 2014-04-01 梅茲製藥有限兩合公司 Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
CA2880701A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
CN106415244B (en) 2014-03-27 2020-04-24 中央研究院 Reactive marker compounds and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP6894239B2 (en) 2014-05-27 2021-06-30 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Compositions and methods for universal glycoforms for enhanced antibody efficacy
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
CA2950440A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-her2 glycoantibodies and uses thereof
TWI732738B (en) 2014-05-28 2021-07-11 中央研究院 Anti-tnf-alpha glycoantibodies and uses thereof
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
WO2016118191A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
AR105910A1 (en) 2015-09-04 2017-11-22 Obi Pharma Inc GLICAN MATRICES AND METHOD OF USE
JP2019515876A (en) 2016-03-08 2019-06-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Methods for module synthesis of N-glycans and their arrays
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
WO2017172990A1 (en) 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
SG11201809024UA (en) 2016-04-22 2018-11-29 Obi Pharma Inc Cancer immunotherapy by immune activation or immune modulation via globo series antigens
WO2018022933A1 (en) 2016-07-27 2018-02-01 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
TWI786054B (en) 2016-07-29 2022-12-11 台灣浩鼎生技股份有限公司 Human antibodies, pharmaceutical compositions and methods
AU2017316663B2 (en) 2016-08-22 2024-02-22 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
CA3044274A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
EP3791873A1 (en) 2019-09-16 2021-03-17 Universite De Bordeaux Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2831854A (en) * 1955-05-24 1958-04-22 Procter & Gamble Method for preparing fatty esters of non-reducing oligosaccharides in the presence of an amide
US3455714A (en) * 1964-09-01 1969-07-15 Hercules Inc Cellulose derivatives of improved dispersibility and process
US3600186A (en) * 1968-04-23 1971-08-17 Procter & Gamble Low calorie fat-containing food compositions
US3579548A (en) * 1968-05-10 1971-05-18 Procter & Gamble Triglyceride esters of alpha-branched carboxylic acids
US3954976A (en) * 1973-12-14 1976-05-04 The Procter & Gamble Company Pharmaceutical compositions for inhibiting absorption of cholesterol
US3963699A (en) * 1974-01-10 1976-06-15 The Procter & Gamble Company Synthesis of higher polyol fatty acid polyesters
US4034083A (en) * 1975-11-03 1977-07-05 The Procter & Gamble Company Compositions for inhibiting absorption of cholesterol
US4005196A (en) * 1976-02-12 1977-01-25 The Procter & Gamble Company Vitaminized compositions for treating hypercholesterolemia
IE44458B1 (en) * 1976-02-12 1981-12-02 Procter & Gamble Compositions for treating hypercholesterolemia
US4005195A (en) * 1976-02-12 1977-01-25 The Procter & Gamble Company Compositions for treating hypercholesterolemia
US4241054A (en) * 1978-12-08 1980-12-23 The Procter & Gamble Company Detoxifying lipophilic toxins
US4264583A (en) * 1979-07-25 1981-04-28 The Procter & Gamble Company Gallstone dissolution compositions and method
US4382924A (en) * 1980-06-25 1983-05-10 The Procter & Gamble Company Palatable composition containing oil or oil-like materials
DE3027611A1 (en) * 1980-07-21 1982-02-18 Bayer Ag, 5090 Leverkusen DI- AND OLIGO-1,2,4-TRIAZOLIDINE-3,5-DIONE AND METHOD FOR THE PRODUCTION THEREOF
US4321263A (en) * 1980-09-30 1982-03-23 Rowell Laboratories, Inc. Psyllium compositions
US4461782A (en) * 1982-02-16 1984-07-24 The Procter & Gamble Company Low calorie baked products
US4518772A (en) * 1983-06-23 1985-05-21 The Proctor & Gamble Company Synthesis of higher polyol fatty acid polyesters using high soap:polyol ratios
US4517360A (en) * 1983-06-23 1985-05-14 The Procter & Gamble Company Synthesis of higher polyol fatty acid polyesters using carbonate catalysts

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100679290B1 (en) * 2005-06-30 2007-02-05 박정휘 A composition comprising an extract of ???­??­201 crude drug complex as an effective ingredient treating or preventing obesity

Also Published As

Publication number Publication date
AU1352188A (en) 1988-09-22
KR970004956B1 (en) 1997-04-10
EP0285201A2 (en) 1988-10-05
US4849222A (en) 1989-07-18
DK162488A (en) 1988-09-25
IE61404B1 (en) 1994-11-02
ATE79544T1 (en) 1992-09-15
CA1314230C (en) 1993-03-09
DK162488D0 (en) 1988-03-24
IE880870L (en) 1988-09-24
DE3873800T2 (en) 1993-01-14
ZA882061B (en) 1988-09-14
NZ223947A (en) 1991-02-26
DK167847B1 (en) 1993-12-27
DE3873800D1 (en) 1992-09-24
JPS6426A (en) 1989-01-05
EP0285201A3 (en) 1990-01-24
PH26694A (en) 1992-09-15
EP0285201B1 (en) 1992-08-19
IL85689A (en) 1993-05-13
AU620541B2 (en) 1992-02-20
JP2581737B2 (en) 1997-02-12

Similar Documents

Publication Publication Date Title
KR880010764A (en) Hypercholesterolemic blood mixture
Drent et al. First clinical studies with orlistat: a short review
HUT45194A (en) Process for production of medical composition
ATE204178T1 (en) METHOD FOR TREATING AND PREVENTING TYPE 1 DIABETIS BY ORAL ADMINISTRATION OF INSULIN
AU6586896A (en) Fatty acid treatment
ES2033464T3 (en) FILLING COMPOSITIONS CONTAINING PSYLLIUM.
KR900009088A (en) Mixed composition for the treatment of hypercholesterolemia
KR890003391A (en) Calcium supplements
ATE6645T1 (en) DIBENZOXAZEPINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5116610A (en) Compositions for treating hypercholesterolemia
DE3579471D1 (en) COMPOSITIONS CONTAINING ORAL DEXTRAN.
KR920702225A (en) Pharmaceutical composition
KR930003913A (en) Methods and pharmaceutical compositions for enhancing the antitussive effect of dextromethorphan
KR880002521A (en) Pharmaceutical formulation
DE3879489T2 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING ADRENOLEUKODYSTROPHY.
Schottstaedt et al. Natural history and course of malignant hypertension
KR940008688A (en) Zinc Tablets Chelated by Essential Fatty Acids
KR930700109A (en) 4,4 '-[9H-fluorene-9-ylidenebis (methylene)]-bispyrimidine for the treatment of neurological diseases

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee